Cisplatin nephrotoxicity affects magnesium and calcium metabolism

Medical and Pediatric Oncology

Volumn 41, Issue 3, 2003, Pages 186-189

  Goren, Marshall P ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Amifostine; Bone; Calcium; Cisplatin; Magnesium; Nephrotoxicity; Sulfhydryl

Indexed keywords

AMIFOSTINE; CALCIUM; CARBOPLATIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; GLUTATHIONE; IFOSFAMIDE; MAGNESIUM; MELPHALAN; THIOL DERIVATIVE;

ANXIETY; BINDING AFFINITY; BOLUS INJECTION; BONE MARROW TOXICITY; CALCIUM METABOLISM; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG PROTEIN BINDING; HUMAN; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPOTENSION; KIDNEY TUBULE ABSORPTION; KIDNEY TUBULE DAMAGE; MAGNESIUM BLOOD LEVEL; MAGNESIUM DEFICIENCY; MAGNESIUM METABOLISM; MAGNESIUM WASTING; NEPHROTOXICITY; NEUROBLASTOMA; NONHUMAN; OSTEOPENIA; OSTEOSARCOMA; PRIORITY JOURNAL; SIDE EFFECT; SOMNOLENCE; SUPPLEMENTATION; VOMITING;

ADULT; AMIFOSTINE; ANTINEOPLASTIC AGENTS; CALCIUM; CHILD; CISPLATIN; CLINICAL TRIALS; HUMANS; KIDNEY; KIDNEY DISEASES; MAGNESIUM; MAGNESIUM DEFICIENCY; OXIDATIVE STRESS; RADIATION-PROTECTIVE AGENTS; WATER-ELECTROLYTE IMBALANCE;

EID: 0042844496     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/mpo.10335     Document Type: Conference Paper

References (42)

1. Lajer H, Daugaard G. Cisplatin and hypomagnesemia. Cancer Treat Rev 1999;25:47-58.
2. Bell DR, Woods RL, Levi JA. Cis-diamminedichloroplatinum-induced hypomagnesemia and renal magnesium wasting. Eur J Cancer Clin Oncol 1985;21:287-290.
3. Schilsky RL, Barlock A, Ozols RF. Persistent hypomagnesemia following cisplatin chemotherapy for testicular cancer. Cancer Treat Rep 1982;66:1767-1769.
4. Markmann M, Rothman R, Reichman B, et al. Persistent hypomagnesemia following cisplatin chemotherapy in patients with ovarian cancer. J Cancer Res Clin Oncol 1991;117:89-90.
5. Brock PR, Koliouskas DE, Barratt TM, et al. Partial reversibility of cisplatin nephrotoxicity in children. J Pediatr 1991;118:531-534.
6. Bianchetti MG, Kanaka C, Ridolfi-Luthy A, et al. Chronic renal magnesium loss, hypocalciuria, and mild hypokalaemic metabolic alkalosis after cisplatin. Pediatr Nephrol 1990;4:219-222.
7. Bianchetti MG, Kanaka C, Ridolfi-Luthy A, et al. Persisting renotubular sequelae after cisplatin in children and adolescents. Am J Nephrol 1991;11:127-130.
8. Ariceta G, Rodriguez-Soriano J, Vallo A, et al. Acute and chronic effects of cisplatin therapy on renal magnesium homeostasis. Med Pediatr Oncol 1997;28:35-40.
9. Koch Nogueira PC, Hadj-Aissa A, et al. Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma. Pediatr Nephrol 1998;12:572-575.
10. Appenroth D, Braunlich H. Age differences in cisplatinum nephrotoxicity. Toxicology 1984;32:343-353.
11. Fleck C, Kretzschel I, Sperschneider T, et al. Renal amino acid transport in immature and adult rats during chromate and cisplatinum-induced nephrotoxicity. Amino Acids 2001;20:201-215.
12. von der Weid NX, Erni BM, Mamie C, et al. (for Swiss Pediatric Oncology Group). Cisplatin therapy in childhood: Renal follow up 3 years or more after treatment. Nephrol Dial Transplant 1999; 14:1441-1444.
13. Arndt C, Morgenstern B, Hawkins D, et al. Renal function following combination chemotherapy with ifosfamide and cisplatin in patients with osteogenic sarcoma. Med Pediatr Oncol 1999; 32:93-96.
14. Lyman NW, Hemalatha C, Viscuso RL, et al. Cisplatin-induced hypocalcemia and hypomagnesemia. Arch Int Med 1980;140: 1513-1514.
15. Estep H, Shaw WA, Watington C, et al. Hypocalcemia due to hypomagnesemia and reversible parathyroid hormone unresponsiveness. J Clin Endocrinol 1969;29:842-848.
16. Anast CS, Winnacker JL, Forte LR, et al. Impaired release of parathyroid hormone in magnesium deficiency. J Clin Endocrinol Metab 1976;42:707-717.
17. Johannesson AJ, Raisz LG. Effects of low medium magnesium concentration on bone resorption in response to parathyroid hormone and 1,25-dihydroxyvitamin D in organ culture. Endocrinology 1983;113:2294-2298.
18. Dai LJ, Ritchie G, Kerstan D, et al. Magnesium transport in the renal distal convoluted tubule. Physiol Rev 2001;81:51-84.
19. Swainson CP, Colls BM, Fitzharris BM. Cis-platinum and distal renal tubule toxicity. New Zealand Med J 1985;98:375-378.
20. Mavichak V, Wong NL, Quamme GA, et al. Studies on the pathogenesis of cisplatin-induced hypomagnesemia in rats. Kidney Int 1985;28:914-921.
21. Magil AB, Mavichak V, Wong NL, et al. Long-term morphological and biochemical observations in cisplatin-induced hypomagnesemia in rats. Nephron 1986;43:223-230.
22. Brown EM, MacLeod RJ. Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 2001;81:239-297.
23. Marcus JC, Altura BT, Altura BM. Serum ionized magnesium in post-traumatic headaches. J Pediatrics 2001;139:459-462.
24. Creedon A, Flynn A, Cashman K. The effect of moderately and severely restricted dietary magnesium intakes on bone composition and bone metabolism in the rat. Br J Nutr 1999;82:63-71.
25. Rude RK, Kirchen ME, Gruber HE, et al. Magnesium deficiency-induced osteoporosis in the rat: Uncoupling of bone formation and bone resorption. Magnes Res 1999;12:257-267.
26. Toba Y, Kajita Y, Masuyama R, et al. Dietary magnesium supplementation affects bone metabolism and dynamic strength of bone in ovariectomized rats. J Nutr 2000;130:216-220.
27. Riond JL, Hartmann P, Steiner P, et al. Long-term excessive magnesium supplementation is deleterious whereas suboptimal supply is beneficial for bones in rats. Magnes Res 2000;13:249-264.
28. Cummings BS, Schnellmann RG. Cisplatin-induced renal cell apoptosis: Caspase 3-dependent and -independent pathways. J Pharmacol Exp Ther 2002;302:8-17.
29. Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 1999;99:2467-2498.
30. Sadowitz PD, Hubbard BA, Dabrowiak JC, et al. Kinetics of cisplatin binding to cellular DNA and modulations by thiol-blocking agents and thiol drugs. Drug Metab Dispos 2002;30:183-190.
31. Yasumasu T, Ueda T, Uozumi J, et al. Comparative study of cisplatin and carboplatin on pharmacokinetics, nephrotoxicity, and effect on renal nuclear DNA synthesis in rats. Pharmacol Toxicol 1992;70:143-147.
32. Litterst CL, Schweitzer VG. Covalent binding of platinum to renal protein from sensitive and resistant guinea pigs treated with cisplatin: Possible role in nephrotoxicity. Res Commun Chem Pathol Pharmacol 1988;61:35-48.
33. Mavichak V, Coppin CM, Wong NL, et al. Renal magnesium wasting and hypocalciuria in chronic cis-platinum nephropathy in man. Clin Sci (Lond) 1988;75:203-207.
34. Erdlenbruch B, Pekrum A, Roth C, et al. Cisplatin nephrotoxicity in children after continuous 72-h and 3 x 1-h infusions. Pediatr Nephrol 2001;16:586-593.
35. Zhang K, Chew M, Yang EB, et al. Modulation of cisplatin cytotoxicity and cisplatin-induced DNA cross-links in HepG2 cells by regulation of glutathione-related mechanisms. Mol Pharmacol 2001;59:837-843.
36. Hensley ML, Schuchter LM, Lindley C, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999;17: 3333-3355.
37. Schuchter LM, Hensley ML, Meropol NJ, et al. Update of recommendations for the use of chemotherapy and radiotherapy protectants: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2002;20:2895-2903.
38. Hartmann JT, Fels LM, Knop S, et al. A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors. Invest New Drugs 2000;18:281-289.
39. Petrilli AS, Oliveira DT, Ginani VC, et al. Use of amifostine in the therapy of osteosarcoma in children and adolescents. J Pediatr Hematol Oncol 2002;24:188-191.
40. Fulda S, Fichtner I, Hero B, et al. Preclinical and clinical aspects on the use of amifostine as chemoprotector in neuroblastoma patients. Med Pediatr Oncol 2001;36:199-202.
41. Renner S, Krumpelmann S, Bruchelt G, et al. Effect of amifostine on neuroblastoma during high dose chemotherapy: In vivo and in vitro investigations. Anticancer Res 2000;20:4531-4538.
42. Fouladi M, Stempak D, Gammon J, et al. Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma. Cancer 2001;92:914-923.